BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast
24/7 Wall St. rates BioMarin Pharmaceutical Inc. (BMRN) as a "BUY" with a 12-month price target of $65.01, representing a 9.3% upside. The analysis, which considers professional targets, profit trajectory, sector, risk, and retail attention, suggests a favorable risk-reward profile for investors. Looking further ahead, the model projects an average price of $77.85 by 2030, with an optimistic 12-month scenario reaching $74.69.
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
BioMarin Pharmaceutical Inc. announced five-year Phase 3 data for POMBILITI® + OPFOLDA® in late-onset Pompe disease (LOPD), presented at the World Muscle Society Annual Congress. The data demonstrated durable motor function outcomes and stabilization of pulmonary function, reinforcing the long-term benefits and safety profile of the treatment. Additionally, BioMarin presented Phase 1/2 data for nivudirsen (BMN 351) for Duchenne muscular dystrophy, showing positive dystrophin expression and favorable tolerability.
Form 4 Biomarin Pharmaceutical Inc For: 1 October By Investing.com
This article from Investing.com announces the filing of Form 4 by Biomarin Pharmaceutical Inc. for October 1st. It also notes a 2.16% decrease in Biomarin's stock symbol BMRN. The article provides minimal information beyond the announcement, typical for a brief financial news update.
After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares.
Gregory R. Friberg, EVP and Chief R&D Officer at BioMarin Pharmaceutical Inc. (BMRN), had 4,086 shares delivered or withheld for tax liability on September 30, 2026, at $60 per share. Following this transaction, Friberg directly holds 47,732 shares of common stock. This insider trading activity was reported as a disposition in a Form 4 filing.
BioMarin lays off 117 California workers to consolidate footprint
BioMarin Pharmaceutical is laying off 117 employees at its Novato, California site, effective December 4, 2026, as part of a consolidation effort to create a "smaller, more focused site." This move follows a previous round of layoffs in New Jersey and is intended to streamline its global footprint, although the company maintains its commitment to patients and affected employees. The job cuts are not related to recent pipeline updates, including the decision to halt Voxzogo development for Noonan syndrome.
BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth
BioMarin Pharmaceutical (BMRN) faces a strategic setback after discontinuing its VOXZOGO program for Noonan syndrome, though this decision was not due to safety or efficacy concerns. Despite this, the company reported a strong Q2 2026 with 20% revenue growth and raised its full-year guidance, beating analyst expectations. Analysts maintain elevated price targets, with the next key checkpoint being the Q3 2026 earnings report in October.
BMRN6299744 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the BioMarin Pharmaceutical Inc. bond BMRN6299744, highlighting its coupon and redemption information. It covers key facts such as issuer details, issue and maturity dates, face value, and minimum denomination. The profile also includes information on interest payments, the coupon payout schedule, and bond redemption specifics.
Profluent Partners With BioMarin to Design Novel Medicines Using AI
Profluent, an AI lab for biology, has announced a collaboration with BioMarin Pharmaceutical Inc. to utilize its AI models for designing and optimizing novel enzyme therapies. This partnership aims to accelerate the drug discovery pipeline for genetically defined conditions by combining Profluent's de novo protein design capabilities with BioMarin's extensive expertise in enzyme replacement therapy. The goal is to identify promising therapeutic candidates more efficiently and advance them into preclinical testing.
Discipline and Rules-Based Execution in BMRN Response
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details specific trading strategies—position, momentum breakout, and risk hedging—developed from AI models with defined entry points, targets, and stop losses. The analysis also provides multi-timeframe signal data, indicating support and resistance levels for various holding periods.
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts
Argus has lowered its target price for BioMarin Pharmaceutical Inc. (BMRN) to $70.00 from its current price of $60.00. BioMarin is a global biotechnology company specializing in therapies for rare genetic diseases. The report was published on September 23, 2026.
BMRN5187965 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the BioMarin Pharmaceutical Inc. BMRN5187965 bond, which has a 1.25% coupon and matures on May 15, 2027. It outlines key facts about the bond and its issuer, BioMarin Pharmaceutical, Inc., including its issue and maturity dates, face value, and corporate overview. The profile also details the bond's interest payment schedule, credit risk assessment classifications, and redemption information, showing upcoming and past coupon payouts.
BioMarin Pharmaceutical Inc. (BM8.F) stock price, news, quote and history
This article provides a detailed overview of BioMarin Pharmaceutical Inc. (BM8.F), including its current stock price, financial statistics, and company profile. It highlights the company's focus on developing therapies for rare diseases and lists several of its key products and pipeline developments. The article also includes performance metrics, earnings trends, and valuation measures for investors.
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish
BioMarin Pharmaceutical (BMRN) closed at $63.94, with analysts like J.P. Morgan maintaining a bullish stance and an $86 target price. The company's second-quarter EPS beat estimates by $0.25, and revenue increased by 20% year-over-year. Despite the stock being below its 52-week high, the strong earnings surprise and analyst consensus for a "Strong Buy" indicate continued positive sentiment.
BioMarin Pharmaceutical stock holds near its 52-week low
BioMarin Pharmaceutical's stock closed near its 52-week low at USD 63.94 on September 18, 2026, despite beating earnings estimates in the second quarter with USD 1.20 EPS and 20% revenue growth. J.P. Morgan maintained a Buy rating and a USD 86 price target, indicating potential upside. The company specializes in rare disease therapies, and its valuation, alongside pipeline execution, remains a key focus for investors given the high price-to-earnings ratio.
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on BioMarin Pharmaceutical Inc. (BMRN), including its current stock price, recent performance, key financial statistics, and company overview. It details the company's biotechnology focus on rare diseases, its product pipeline, and analyst ratings. The page also includes performance comparisons against the S&P 500 and earnings trends.
BioMarin Stops Voxzogo Development for Noonan Syndrome
BioMarin Pharmaceutical has decided to discontinue the development of Voxzogo (vosoritide) for Noonan syndrome, citing study feasibility and the current treatment landscape, not safety or efficacy concerns. This follows an earlier halt in development for other short stature indications due to an adverse event. Despite this discontinuation, Voxzogo, a key revenue driver for BioMarin, continues to pursue label expansion for hypochondroplasia and idiopathic short stature, while also navigating increasing competition from rivals like Ascendis Pharma and BridgeBio Pharma.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has appointed Robert Plenge, M.D., Ph.D., the EVP and Chief Research Officer of Bristol Myers Squibb, to its Board of Directors, effective September 10, 2026. This move is seen as a significant governance and talent decision that could influence BioMarin's R&D strategy for its rare disease pipeline. Plenge brings extensive experience in translational medicine and genetics from his previous roles at Bristol Myers Squibb, Celgene, and Merck.
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) director Robert M. Plenge was granted 6,140 restricted stock units on September 10, 2026, as equity compensation. This transaction, reported via a Form 4 filing, involved no cash exercise price, and Plenge's direct holdings after the award total 6,140 shares. No Rule 10b5-1 trading plan was reported in connection with this grant.
Form 8K Biomarin Pharmaceutical Inc For: 15 September By Investing.com
This article from Investing.com announces the filing of a Form 8K by BioMarin Pharmaceutical Inc. on September 15th. The brief piece serves as a notification regarding this corporate filing, without providing further details on the content of the Form 8K. It also lists related market data and trending stocks.
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. has appointed Robert Plenge, M.D., Ph.D., Chief Research Officer and Head of Research at Bristol Myers Squibb, to its Board of Directors, effective September 10, 2026. Dr. Plenge brings extensive experience in human genetics, drug discovery, and the pharmaceutical industry. His appointment is expected to provide valuable scientific perspective as BioMarin develops its research capabilities and expands its pipeline for genetic conditions.
BioMarin Pharmaceutical Inc. Announces Appointment of Robert Plenge to Its Board of Directors and Science and Technology Committee, Effective September 10, 2026
BioMarin Pharmaceutical Inc. has announced the appointment of Robert Plenge, M.D., Ph.D., to its Board of Directors and Science and Technology Committee, effective September 10, 2026. Dr. Plenge currently serves as Executive Vice President, Chief Research Officer, and Head of Research at Bristol Myers Squibb, bringing extensive experience from leadership roles at Celgene Corp. and Merck & Co., and academic positions at Harvard Medical School. He holds degrees from Case Western Reserve University and the University of California, San Diego, and also serves on the boards of Alltrna and the PhRMA Foundation.
BioMarin (NASDAQ: BMRN) director reports no stake
BioMarin Pharmaceutical Inc. (BMRN) director Robert M. Plenge has filed an initial statement of beneficial ownership (Form 3) reporting no transactions, no derivative positions, and no share holdings in the company. This filing indicates Plenge has become a reporting person for BioMarin, but currently holds no stake. The document confirms that there are no buy or sell transactions and no Rule 10b5-1 trading plan affirmed for him at this time.
Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com
This article reports that BioMarin Pharmaceutical Inc. filed a Form 8K on September 14. The filing is brief, simply stating the company name and date of the filing. It includes the stock symbol BMRN and its current performance.
BioMarin Pharmaceutical appoints Robert Plenge to board of directors
BioMarin Pharmaceutical (NASDAQ:BMRN) has expanded its board of directors from ten to eleven members, appointing Robert Plenge, M.D., Ph.D., as a new independent non-employee director, effective September 10. Dr. Plenge will also join the board’s Science and Technology Committee and will receive standard director compensation, including restricted stock units valued at $400,000. This announcement follows recent news of BioMarin's global settlement with Ascendis Pharma regarding patent disputes for Yuviwel, which has led to several analyst firms adjusting their price targets for BMRN.
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. has appointed Dr. Robert Plenge, Chief Research Officer of Bristol Myers Squibb, to its Board of Directors, effective September 10, 2026. Dr. Plenge brings extensive experience in human genetics, drug discovery, and the pharmaceutical industry, having previously held leadership roles at Celgene Corp. and Merck & Co. His appointment is expected to significantly contribute to BioMarin's research capabilities and pipeline expansion in genetic conditions.
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc. (BMRN) saw its shares jump 5% following a global patent settlement with Ascendis Pharma A/S (ASND) over Ascendis's achondroplasia drug Yuviwel. The agreement resolves ongoing litigation across multiple jurisdictions and includes a royalty payment structure where BioMarin will receive 20% of Yuviwel's net sales in the US and 18% in the EU, Brazil, and South Korea until May 2030, in exchange for a non-exclusive license. This settlement provides BioMarin with a consistent revenue stream and removes litigation uncertainty for Ascendis, allowing unrestricted commercialization of Yuviwel.
H.C. Wainwright reiterates Biomarin stock rating at neutral
H.C. Wainwright maintained its Neutral rating and $60 price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) following new competitor data for an infant achondroplasia treatment. Despite BioMarin's 20% U.S. royalty on the competing drug, YUVIWEL, its 52-dose infant schedule presents a commercial risk to BioMarin's VOXZOGO. Analysts have revised earnings downwards for BioMarin, though the company remains profitable, with its next significant catalyst being the third-quarter 2026 earnings report and an FDA review for another treatment.
(BMRN) Movement Within Algorithmic Entry Frameworks
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) using algorithmic entry frameworks. It identifies weak near-term sentiment and a mid-channel oscillation pattern, suggesting a significant risk-reward short setup. The analysis provides three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, alongside multi-timeframe signal analysis.
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence
BioMarin Pharmaceutical Inc. announced positive results from its Phase 3 CANOPY-HCH-3 study of VOXZOGO (vosoritide) in children with hypochondroplasia, which were published in NEJM Evidence and presented at the ESPE 2026 Annual Meeting. The study demonstrated statistically significant improvements in growth measures like annualized growth velocity, standing height, height Z-score, and arm span. BioMarin has submitted these data to the FDA for a supplemental New Drug Application to expand VOXZOGO's treatment indication to include children with hypochondroplasia.
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock
Eric George Davis, EVP at BioMarin Pharmaceutical, sold 17,557 shares of the company's stock for a total of $1,163,748 on September 3, according to an SEC filing. This insider transaction comes as BioMarin Pharmaceutical shares were trading down 0.48% at $65.47. The article also provides a financial overview of BioMarin, highlighting its revenue growth, profitability insights, debt management, and valuation metrics.
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin Pharmaceutical has settled a patent dispute with Ascendis Pharma, turning a competitive threat into a royalty-bearing asset. Ascendis will pay BioMarin royalties on its achondroplasia drug Yuviwel, which competes with BioMarin's Voxzogo. While this deal mitigates some competitive risk by giving BioMarin an economic interest in Yuviwel's sales, the achondroplasia market is expected to become more competitive with new entrants like BridgeBio Pharma's infigratinib.
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin Pharmaceutical has successfully converted a competitive threat from Ascendis Pharma's Yuviwel, a rival achondroplasia drug, into a royalty-bearing asset. Through a patent dispute settlement, BioMarin will receive royalties on Yuviwel sales, effectively gaining an economic interest in a drug that could otherwise compete with its own key product, Voxzogo. Despite this strategic move, competitive challenges remain for BioMarin, especially with BridgeBio Pharma's new oral therapy on the horizon.
BioMarin Announces Close of the Alesta Therapeutics Acquisition
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has completed its acquisition of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia (HPP), to its clinical pipeline. ALE1 is an oral small molecule for treating the rare genetic bone disease and is currently in Phase 12a clinical trials. This acquisition strengthens BioMarin's skeletal conditions portfolio and expands its focus on genetically defined conditions.
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin Pharmaceutical Inc. has reached a global settlement with Ascendis Pharma A/S regarding patent disputes concerning Ascendis's Yuviwel. Under the agreement, Ascendis will pay BioMarin royalties of 20% on net sales of Yuviwel in the U.S. and 18% in the EU, Brazil, and South Korea until May 2030, retroactive to the first commercial sale. This settlement resolves all pending patent-related proceedings and intellectual property claims globally, including in the U.S. International Trade Commission.
Raymond James raises BioMarin stock price target on patent settlement
Raymond James increased its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $109 from $105, maintaining an Outperform rating, following a patent settlement with Ascendis Pharma. The settlement involves BioMarin receiving royalty payments from Ascendis for its Yuviwel drug, which is expected to provide significant economics and accelerate BioMarin's deleveraging efforts. Other analysts have also adjusted their ratings and price targets for BioMarin in light of this settlement and the company's planned acquisition of Alesta Therapeutics.
Ascendis pays 20% royalties in patent settlement with BioMarin
Ascendis Pharma has agreed to a patent settlement with BioMarin, resolving intellectual property disputes in five countries over Ascendis' achondroplasia drug Yuviwel. Under the agreement, Ascendis will pay BioMarin royalties of 20% on U.S. net sales and 18% on EU, Brazil, and South Korea net sales of Yuviwel until May 2030. This deal allows Ascendis to continue developing its CNP franchise and clears legal hurdles, while BioMarin gains a significant revenue stream estimated to reach $720 million by 2030.
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin Pharmaceutical Inc. has reached a global settlement with Ascendis Pharma A/S regarding patent disputes. Under the agreement, Ascendis will pay BioMarin royalties on net sales of its drug Yuviwel: 20% in the U.S. (retroactive to first commercial sale) and 18% in the European Union, Brazil, and South Korea until May 2030. This resolution covers all pending patent-related proceedings and acknowledges BioMarin's pioneering innovations in C-type natriuretic peptide (CNP) technology.
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why
BioMarin Pharmaceutical (BMRN) shares rose 2% after announcing the acquisition of Alesta Therapeutics for an upfront payment of $275 million and up to $215 million in milestone payments. The deal brings ALE1, an experimental oral tablet for hypophosphatasia, into BioMarin's portfolio, offering a potential oral alternative to current injectable treatments. Despite the acquisition, H.C. Wainwright lowered its price target for BioMarin from $60 to $59, maintaining a Neutral rating, due to the need for further efficacy data for ALE1.
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC
Paralel Advisors LLC acquired 40,919 shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, valued at approximately $2.34 million, as institutional investors now collectively own 98.71% of the company's outstanding shares. BioMarin exceeded quarterly expectations with $1.20 EPS and $989.7 million in revenue, leading to a "Moderate Buy" consensus rating among analysts, despite mixed sentiment regarding recent acquisitions and future growth prospects. The company's stock opened at $67.68, near its 12-month high of $70.98, reflecting its strong financial performance and positive analyst upgrades.
Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN
Eagle Health Investments LP has acquired 624,676 shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, making it their fifth-largest holding. This acquisition, valued at approximately $35.7 million, contributes to institutional investors collectively owning 98.71% of BioMarin. The news follows BioMarin's agreement to acquire Alesta Therapeutics, boosting its rare-disease portfolio, and a "Moderate Buy" analyst consensus with an average price target of $88.83.
BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98
BMO has initiated coverage on BioMarin Pharmaceutical Inc. (BMRN.O) with an "Outperform" rating. The firm has set a price target of $98 for the biotechnology company. This information was reported by Reuters.
BioMarin to acquire Alesta Therapeutics for up to $490 million
BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Alesta Therapeutics for up to $490 million. The acquisition involves an upfront cash payment of $275 million for Alesta's lead asset, ALE1, a therapy for hypophosphatasia, with potential additional milestone payments of up to $215 million. Existing Alesta shareholders will retain interests in a newly formed entity for non-ALE1 assets, and the transaction is expected to close in Q3 2026.
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated
BMO Capital Markets initiated coverage of BioMarin Pharmaceutical (BMRN) with an "outperform" rating. The firm believes that investors are overstating the potential sales erosion of BioMarin's key treatment, Voxzogo, indicating a potential 46% upside. BioMarin's current trading valuation is also noted to be significantly lower than its peers.
H.C. Wainwright cuts BioMarin stock price target on acquisition costs
H.C. Wainwright has lowered its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $59 from $60, maintaining a Neutral rating, due to costs associated with BioMarin's acquisition of Alesta. Despite this, the stock trades near its 52-week high, and InvestingPro suggests it is undervalued. The acquisition, valued at $275 million upfront with potential additional milestones, aims to secure ALE1, a clinical-stage asset for hypophosphatasia.
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN
GSA Capital Partners LLP has invested $944,000 in BioMarin Pharmaceutical Inc. by acquiring 16,501 shares during the second quarter, making them a new institutional stakeholder. This move comes as other institutional investors have also adjusted their positions, and BioMarin continues to receive a "Moderate Buy" consensus rating from analysts with an average price target of $88.41. The company recently reported strong quarterly results, exceeding revenue and EPS expectations, and announced the acquisition of Alesta Therapeutics, strengthening its long-term growth outlook.
REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics
RTW Biotech Opportunities Ltd ("RTW Bio") announced that BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company. The deal includes an upfront cash payment of $275 million for Alesta's lead asset, ALE1, which represents a 41% uplift to RTW Bio's carrying value, with potential for an additional $215 million in milestone payments. This marks the sixth acquisition from RTW Bio's portfolio in 2026, validating its strategy of investing in early-stage, differentiated science.
BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company
BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen as an effort to spur growth for the company.
BioMarin to Acquire Alesta Therapeutics for Up to $490 Million
BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics for up to $490 million, securing Alesta's lead clinical program, ALE1, an oral therapy for hypophosphatasia (HPP). This acquisition, consisting of an upfront payment of $275 million and up to $215 million in milestones, will expand BioMarin's rare disease pipeline and skeletal conditions portfolio. Alesta will spin out its other assets and employees before the deal closes, making ALE1 the sole focus of the acquisition.
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351
This M&A roundup details several significant deals in the pharmaceutical sector, including LEO Pharma's acquisition of dersimelagon for rare skin diseases, BioMarin's purchase
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
BioMarin Pharmaceutical has acquired Alesta Therapeutics for an upfront payment of $275 million, with an additional $215 million in potential milestones. This acquisition aims to position BioMarin to compete with AstraZeneca in the rare bone disease market, specifically hypophosphatasia (HPP), with Alesta's oral drug candidate, ALE1. The deal allows BioMarin to target the adult HPP market, which is currently underserved by existing treatments, and strengthens its skeletal condition unit.
